ABEO Stock — Abeona Therapeutics Inc.: Cash, EV, Pipeline

Share price

$5.57

Market cap

$318.5M

Cash

$146.8M

Enterprise value

$173.4M

Balance sheet

Cash	$146.8M
Debt	$1.7M
Net cash	$145.1M
Enterprise value	$173.4M
Basic shares	57.2M shares
Fully diluted shares	75.7M shares
Fully diluted market cap	$421.4M
Cash per share	$2.57

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ABEO daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Apr 12 - May 24	UX111	Phase 3	MPS IIIA; Sanfilippo Syndrome; Sanfilippo A	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

ZEVASKYN (prademagene zamikeracel)

Approved · Active Modality: autologous gene-modified cellular sheets (gene-modified epidermal sheets)

Target COL7A1

Indications

Recessive dystrophic epidermolysis bullosa (RDEB) wounds (Approved)

Status note FDA approved April 28, 2025; described as the first and only autologous cell-based gene therapy for RDEB wounds.

ABO-701

Preclinical · Active Modality: engineered T-cell therapy (synthetic immune receptor SIR-T)

Target PSMA

Partnerships Reverence Enterprises, LLC: $7.0M upfront; up to $1.0M event-based milestones

Indications

Prostate cancer (Stage not disclosed)

Status note 10-Q calls ABO-701 a recently licensed engineered T-cell therapy targeting PSMA for prostate cancer and separately describes the March 18, 2026 Reverence license for the PSMA SIR-T autologous T-cell product (IND to be filed, Phase 1 study planned); the filing does not state ABO-701 and the SIR-T product are the same candidate. Indication stage pending IND.

ABO-503

Preclinical · Active Modality: AAV gene therapy (RS1 packaged in AAV204 AIM capsid)

Target RS1

Indications

X-linked retinoschisis (XLRS) (Stage not disclosed)

Status note Deprioritized per Q2 2026 10-Q (soft wind-down, not discontinued). 10-K: pre-IND meeting April 2023; animal efficacy/toxicology and cGMP manufacturing postponed to 2026. Beacon Therapeutics out-licenses the AAV204 capsid for select ophthalmology targets (upfront + milestones + tiered royalties).

ABO-504

Preclinical · Active Modality: dual AAV vector gene therapy (Cre-LoxP recombinase system reconstituting full-length ABCA4)

Target ABCA4

Indications

Stargardt disease (Stage not disclosed)

Status note Deprioritized per Q2 2026 10-Q (soft wind-down, not discontinued). 10-K: pre-IND meeting June 2023.

ABO-505

Preclinical · Active Modality: AAV gene therapy (Opa1 delivered via AAV204)

Target Opa1

Indications

Autosomal dominant optic atrophy (ADOA) (Stage not disclosed)

Status note Deprioritized per Q2 2026 10-Q (soft wind-down, not discontinued). Para-retinal injection; preclinical only per 10-K.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	EB-101 Surgical application of RDEB wounds
Lead indication	Epidermolysis Bullosa
Lead phase	Phase 3
Active trials	4
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05725018	Phase 3	Active, not recruiting	Sponsor	ABEO	—	Epidermolysis Bullosa; Recessive Dystrophic Epidermolysis Bullosa; RDEB	—
NCT07717736	Not disclosed	Not yet recruiting	Sponsor	ABEO	—	Epidermolysis Bullosa (EB); Recessive Dystrophic Epidermolysis Bullosa (RDEB); Dystrophic Epidermolysis Bullosa (DEB)	—
NCT05708677	Not disclosed	Enrolling by invitation	Sponsor	ABEO	—	RDEB	—
NCT07700966	Not disclosed	Recruiting	Sponsor	ABEO	—	Recessive Dystrophic Epidermolysis Bullosa	—
NCT02716246	Phase 3	Recruiting	Collaborator	RARE	—	MPS IIIA; Sanfilippo Syndrome; Sanfilippo A	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Abeona Therapeutics, Inc on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

ABEO — Abeona Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials